Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 6/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 5/20 | 0.40 |
| ▸ | MAPK12 | P53778 | 5/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 5/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2029284 | 0.85 | MAPK13 (0.41) | MAPK14MAPK13MAPK12MAPK11CES2 | |
| SCHEMBL2031846 | 0.84 | MDM2 (0.34) | MAPK14MAPK11CES2CES1TP53 | |
| SCHEMBL375572 | 0.82 | MDM2 (0.40) | MAPK14MDM2 | |
| SCHEMBL2034477 | 0.81 | MAPK13 (0.36) | MAPK14MAPK13MAPK12MAPK11CES2 | |
| SCHEMBL2032961 | 0.76 | MAPK13 (0.33) | MAPK14MAPK13MAPK12MAPK11TP53 | |
| SCHEMBL375778 | 0.75 | MAPK14 (0.42) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL963511 | 0.74 | CES2 (0.47) | CES2CES1L3MBTL1MDM2 | |
| SCHEMBL5069128 | 0.74 | MAPK13 (0.41) | MAPK14MAPK13MAPK12MAPK11ALDH1A1 | |
| SCHEMBL1504495 | 0.72 | TTR (0.46) | MAPK14MAPK13MAPK12MAPK11TP53 | |
| SCHEMBL2036069 | 0.72 | MAPK13 (0.32) | MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1810972-B1 | NITROGENOUS HETEROCYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO (JP) | 2012-01-25 | — | — | EP | disclosed |
| US-7968572-B2 | Nitrogen-containing heterocyclic compound and pharmaceutical application thereof | ONO PHARMACEUTICALS CO., LTD. (JP) | 2011-06-28 | — | — | US | disclosed |
| US-7713998-B2 | Nitrogenous heterocyclic compound and pharmaceutical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-05-11 | — | — | US | disclosed |
| US-20100063104-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND PHARMACEUTICAL APPLICATION THEREOF | ONO PHARMACEUTICAL CO., LTD., (JP) | 2010-03-11 | — | — | US | disclosed |
| EP-1932840-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND PHARMACEUTICAL APPLICATION THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-06-18 | — | — | EP | disclosed |
| US-20070265308-A1 | Nitrogenous Heterocyclic Compound and Pharmaceutical Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-15 | — | — | US | disclosed |
| EP-1810972-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265308-A1 | Nitrogenous Heterocyclic Compound and Pharmaceutical Use Thereof | MAPK1, MAPK13, MAPK6 | MAPK14 6/4885MAPK13 2/4885MAPK12 8/4885 |
| US-20100063104-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND PHARMACEUTICAL APPLICATION THEREOF | NOS2, NOS1, MAPK1 | MAPK14 8/4885MAPK13 12/4885MAPK12 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.